Sign in
Taking people in South KoreaNo phase

Studies dapagliflozin in people with type 2 diabetes and high blood pressure

Observes how dapagliflozin works and its safety in adults with type 2 diabetes and hypertension.

Key facts

Who runs it
Boryung Pharmaceutical Co., Ltd
Where
Incheon, South KoreaSee the site
Trial code
Registry title
A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension
Status
Recruiting
People taking part
9,000 people, planned
Started
26 Jul 2023
Planned end
21 Oct 2025
Type of study
Observational
Record updated
15 September 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes and high blood pressure who are about to start Trudapa Tab. or Trudapa M SR Tab. (dapagliflozin).

Age
19 years and older
Sex
All sexes can join.
Disease stage
Type 2 diabetes mellitus together with hypertension (high blood pressure).
Earlier treatment
Must not have taken dapagliflozin within 4 weeks of baseline (Visit 1).

Main reasons for not taking part

  • Secondary hypertension (high blood pressure caused by another disease)
  • Took dapagliflozin within 4 weeks of baseline (Visit 1)
  • Expected to need insulin during the study
  • Pregnant or breast-feeding women

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Those diagnosed with type 2 diabetes mellitus accompanied by hypertension who are scheduled to be administrated Trudapa Tab. or Trudapa M SR Tab
  • Those who voluntarily signed a written personal information agreement to participate in this clinical study
  • Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion

Who cannot take part

  • Patients with secondary hypertension: Secondary hypertension is not limited to the following diseases; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.)
  • Those who have a history of taking dapagliflozin within 4 weeks of baseline (Visit 1)
  • Those who are expected to need insulin prescription during the study period
  • Pregnant women, breast-feeding women

Where in South Korea

  • Gachon University Gil Medical CenterIncheon, South KoreaContact: Ki-young LeeTaking people

About the trial

What the trial wants to find out

The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertension

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Multicenter, Prospective, Non-interventional, Observational Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension
Plain-language title
Studies dapagliflozin in people with type 2 diabetes and high blood pressureGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
15 September 2025